Here are five facts:
1. The company’s shares opened at $46.49 on Jan. 26.
2. On Jan. 12, Canaccord Genuity analysts rated NuVasive as “buy.”
3. NuVasive has a P/E ratio of 38.08.
4. The company’s 12-month low is $41.52 and its 12-month high is $56.61.
5. The 50-day moving average is $51.29 and the 200-day moving average is $51.93.
More articles on devices:
C2 Therapeutics expands leadership team — 4 highlights
St. Jude Medical stock dips by 0.2%: 5 things to know
SpineGuard names Steve McAdoo VP: 3 notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
